Background
==========

Post-treatment sexual function is a primary determinant of satisfaction following prostate radiotherapy \[[@B1],[@B2]\]. Erectile dysfunction (ED) occurs commonly following external beam radiation therapy (EBRT) and/or brachytherapy \[[@B3]\]. The incidence of ED is dependent on the potency definition \[[@B4],[@B5]\] and on the manner of data collection (i.e. patient or physician reported) \[[@B6]\]. Patients with radiation-induced impotence report a decrease in the quality and reliability of erection, ability to reach orgasm and overall ability to function sexually \[[@B7]\]. ED develops months to years after radiation therapy without recovery \[[@B2]\]. Patient characteristics such as a history of baseline ED \[[@B8]\], older age \[[@B9]\], obesity, comorbidities and pretreatment sexual aid usage may increase an individual's risk of radiation induced ED \[[@B10]\]. In addition, utilization of androgen deprivation therapy (ADT) \[[@B2]\] and radiation-induced hypogonadism \[[@B11]\] can adversely affect sexual outcomes while post-treatment utilization of sexual aids may enhance them \[[@B12]-[@B14]\].

The etiology of radiation induced ED is currently unclear but may involve damage to the neurovascular bundles (NVBs) \[[@B15]\], crura \[[@B16],[@B17]\] and/or penile bulb (PB) \[[@B16],[@B18]\]. Thus treatment-related factors such as the radiation dose to these adjacent sexual structures may contribute to the incidence and severity of ED. The risk of ED may be related to the volume of the crura/penile bulb in the high dose area \[[@B16]\]. To minimize ED, it is currently recommended that the median dose to the penile bulb be limited to \< 50 Gy with conventionally fractionated EBRT \[[@B19]\]. Studies have shown that advanced radiation technologies such as intensity modulated radiation therapy (IMRT) may decrease the dose to the crura/penile bulb and potentially decrease ED \[[@B20],[@B21]\].

The optimal radiation schedule for the treatment of prostate cancer is under active clinical investigation. Recent data suggest that large radiation fraction sizes are radiobiologically favorable over lower fraction sizes in prostate cancer \[[@B22],[@B23]\]. The α/β for prostate cancer may be as low as 1.5 Gy \[[@B22]\]. If the α/β for prostate cancer is less than 3 Gy, which is generally the value accepted for late sexual complications, the linear-quadratic model predicts that delivering large radiation fraction sizes will result in improved local control with a similar rate of sexual function complications.

SBRT is a safe and effective treatment for clinically localized prostate cancer \[[@B24]-[@B26]\]. The use of large fraction sizes in SBRT offers the potential radiobiological benefits of hypofractionation and potentially may minimize radiation-associated ED by reducing the volume of critical structures receiving high radiation doses. The CyberKnife robotic radiosurgical system uses image guidance to track implanted fiducials to account for intrafraction prostatic motion \[[@B27],[@B28]\]. This reduces the uncertainty of the location of the prostate and allows treatment to be delivered with a smaller treatment volume expansion, which may reduce the doses delivered to the adjacent sexual structures. Initial reports suggest that the incidence of ED following SBRT is comparable to other radiotherapy modalities \[[@B29]\]. The goal of this study is to report the sexual outcomes following SBRT for clinically localized prostate cancer in previously potent men.

Methods
=======

Patient selection
-----------------

Patients eligible for this study were those who had histologically-confirmed prostate cancer and were potent (patient-reported response of "firm enough for intercourse" on Question 9 of the baseline EPIC-26) with or without sexual aids prior to treatment. Patients who received ADT were excluded from this study. Institutional IRB approval was obtained for retrospective review of data that was prospectively collected in our institutional database.

SBRT treatment planning and delivery
------------------------------------

SBRT treatment planning and delivery were conducted as previously described \[[@B30]\]. Briefly, gold fiducials were placed into the prostate. Fused CT and MR images were used for treatment planning. The clinical target volume (CTV) included the prostate and the proximal seminal vesicles. The planning target volume (PTV) equaled the CTV expanded 3 mm posteriorly and 5 mm in all other dimensions. The prescription dose was 35--36.25 Gy to the PTV delivered in five fractions of 7--7.25 Gy over one to two weeks. The PB (proximal portion of the corpus spongiosum) was contoured \[[@B31]\] and evaluated with dose-volume histogram analysis during treatment planning using Multiplan (Accuray Inc., Sunnyvale, CA) inverse treatment planning. The dose-volume histogram (DVH) goal was for \< 50% PB volume receiving 29.5 Gy. Assuming an α/β of 3 Gy for late sexual complications, this is biologically equivalent to approximately 50 Gy administered in 2 Gy fractions \[[@B32]\]. To minimize the risk of local recurrence, the dose to the NVBs was not restrained. Target position was verified during treatment using paired, orthogonal x-ray images.

Follow-up and statistical analysis
----------------------------------

Prostate-specific antigen (PSA) and total testosterone levels were obtained before treatment and during routine follow-up visits every 3 months for the first year and every six months for the second year. Sexual function was assessed with the Expanded Prostate Index Composite (EPIC)-26 \[[@B7]\] and Utilization of Sexual Medication/Device questionnaires at baseline and at all follow-ups. The EPIC-26 sexual function domain includes five questions related to sexual function and one question related to sexual bother (degree of interference or annoyance caused by limitations in sexual function) \[[@B33]\]. The sexual functions assessed included quality of erection (potency), ability to have erection, reliability of erections, ability to reach orgasm and overall ability to function sexually. The definition of potency and sexual activity were based on the patient-reported response to Question 9 on the EPIC-26. Potency was defined as the ability to have an erection firm enough for intercourse \[[@B34]\] while sexual activity was defined as the ability to have an erection firm enough for masturbation and foreplay \[[@B4]\].

Student's t-test and chi-square analysis were used to assess differences in ongoing PSA, testosterone and quality of life scores in comparison to baseline. Sample medians and ranges were used to describe continuous variables including PSA and testosterone. For each EPIC question, the responses were grouped into two to three clinically relevant categories. To statistically compare changes between time points, the levels of responses were assigned a score and the significance of the mean changes in the scores was assessed by paired *t* test. EPIC scores for the sexual domain and its individual questions range from 0--100 with lower values representing worsening sexual symptoms. The minimally important difference (MID) in EPIC score was defined as a change of one-half standard deviation (SD) from the baseline \[[@B35]\]. To limit the effect of attrition bias, statistical analysis was limited to time points in which ≥ 80% of the patient data were available.

The impact of baseline patient characteristics on potency rates two years post-SBRT were evaluated by univariate and multivariate analyses. Univariate analysis of variance (ANOVA) was used to detect significant relationship between patient characteristics and potency at 2 years post treatment. In multivariate analysis, stepwise ordinal logistic regression modeling was used to determine independent factors predicting sexual function outcome. The baseline patient characteristics that were included as variables in the univariate and multivariant analyses included age, race, partner status, comorbidity, body mass index (BMI), risk group, work status, Sexual Health Inventory for Men (SHIM) score, erectile function and sexual aid usage. All tests were two-tailed, and a *p* value \<0.05 was considered significant. IBM® SPSS version 21 and MedCalc® version 12.6.1.0 were used to perform the statistical analyses.

Results
=======

From February 2008 to March 2011, 216 prostate cancer patients were treated per our institutional SBRT monotherapy protocol. Ninety-seven men who were identified as being potent at the initiation of therapy and had a minimal follow up of two years post-treatment were included in this review (Table [1](#T1){ref-type="table"}). They were ethnically diverse with a median age of 66.8 years (range, 48--82 years). The median pre-treatment total serum testosterone level was 11.4 nmol/L (range, 4.4 - 27.9 nmol/L). 43 patients were low-, 50 intermediate-, and 4 high-risk. 49.5% patients had ED prior to treatment (baseline SHIM ≤ 21) with a median baseline SHIM of 22 (range, 3--25). 36.1% of patients were utilizing sexual aids prior to SBRT. Phosphodiesterase 5 (PDE5) inhibitors were utilized most commonly (36%) followed by vacuum devices (1%). No patients utilized transurethral suppositories or penile injections prior to treatment.

###### 

Baseline patient characteristics and treatment

                      **Patients(n = 97)**                            
  ---------------------------------------- -------------------------- -------------------------------------
                            **Age(years)**                   Age ≤ 60                            14 (14.4%)
                                                       60 \< Age ≤ 70                            55 (56.7%)
                                                            Age \> 70                            28 (28.9%)
                                  **Race**                                                                 
                                                                White                            47 (48.5%)
                                                                Black                            46 (47.4%)
                                                                Other                              4 (4.1%)
        **Median Pre-Tx PSA(ng/mL)Median**                                              5.9 (1.8-32.5)ng/mL
    **Median Pre-Tx testosterone(nmol/L)**                                            11.4 (4.4-27.9)nmol/L
                        **Partner status**                                                                 
                                                            Partnered                            73 (75.3%)
                                                        Not partnered                            24 (24.7%)
       **Charlson comorbidity index(CCI)**                                                                 
                                                                    0                            78 (80.4%)
                                                                    1                            13 (13.4%)
                                                                    2                              5 (5.2%)
                                                                    3                                1 (1%)
                  **Body mass index(BMI)**                                                                 
                                                                 \<25                            24 (24.7%)
                                                             25-29.99                            46 (47.4%)
                                                             30-34.99                            23 (23.7%)
                                                                 ≥ 35                              4 (4.1%)
                 **Risk group(D'Amico's)**                                                                 
                                                             Low risk                            43 (44.3%)
                                                    Intermediate risk                            50 (51.5%)
                                                            High risk                              4 (4.1%)
                           **Work status**                                                                 
                                                              Working                            57 (58.8%)
                                                          Non-working                           40 ((41.2%)
          **Pre**-**treatment SHIM score**                                                                 
                                                        22-25 (No ED)                            49 (50.5%)
                                                      17-21 (Mild ED)                            32 (33.0%)
                                             12-16 (Mild Moderate ED)                            10 (10.3%)
                                                   8-11 (Moderate ED)                              2 (2.1%)
                                                     \< 8 (Severe ED)   ^\*(No\ Sexual\ Activity)^ 4 (4.1%)
                            **Sexual aid**                                                                 
                                                                 None                            62 (63.9%)
                                                                 Oral                            35 (36.1%)
                                                               Vacuum                              1 (1.0%)
                                                Suppository/injection                                0 (0%)
                              **Dose(Gy)**                                                                 
                                                                36.25                            87 (89.7%)
                                                                   35                              9 (9.3%)
                                                                Other                              1 (1.0%)

Ninety percent of patients were treated with 36.25 Gy in five 7.25 Gy fractions (Table [1](#T1){ref-type="table"}). The median follow-up was 2.7 years. The median pre-treatment PSA of 5.9 ng/ml declined to a median two years post-treatment of 0.5 ng/ml. There was one biochemical failure, occurring in an intermediate-risk patient. The overall two-year actuarial biochemical relapse free survival was 99%. No patient initiated ADT in the first two years following therapy.

Erections sufficient for intercourse declined following treatment: 100% (baseline); 67.8% (6 months); 62.2% (12 months); 57% (18 months) and 54.4% (24 months) (Table [2](#T2){ref-type="table"}) which were statistically significant (*p* \< 0.0001) at all time points. The decline in potency at two years was unlikely due solely to aging, as the average age of potent patients (66.1 y/o) was not statistically different from non-potent patients (68.0 y/o) (*p* = 0.17). However, at two year post-SBRT, 77.8% of patients had erections that were satisfactory for sexual activity including masturbation and foreplay (Table [2](#T2){ref-type="table"}). A Charlson Comorbidity Index of ≥ 1 was significantly associated with a decreased probability of potency preservation at two years on univariate (*p* = 0.007) , but was not significant on multivariate analysis (*p* = 0.246) (Table [3](#T3){ref-type="table"}). Sexual aid usage prior to SBRT was associated with an increased probability of potency preservation two years following treatment on both univariant (*p* = 0.010) and multivariant analysis (*p* = 0.037) (Table [3](#T3){ref-type="table"}). No other baseline patient characteristics were significantly associated potency at two years following SBRT. Two years post-treatment, overall sexual aid utilization increased to 48.9%: oral medications (48.9%), vacuum device (6.7%), urethral suppository (2.2%) and penile injection (2.2%) (Table [4](#T4){ref-type="table"}). No men utilized a penile prosthesis.

###### 

**Quality of erection following SBRT for prostate cancer** (**patient**-**reported responses to question 9 of the EPIC**-**26**)

                             **Follow up(months)** **Start**   **3**      **6**      **9**      **12**     **18**     **24**
  ------------------------------------------------ ----------- ---------- ---------- ---------- ---------- ---------- ----------
                       Firm enough for intercourse 100.0%      73.7%      67.8%      66.7%      62.2%      57.0%      54.4%
    Firm enough for masturbation and foreplay only 0.0%        9.5%       18.4%      17.2%      17.8%      26.6%      23.3%
                  Not firm for any sexual activity 0.0%        16.8%      13.8%      16.1%      20.0%      16.5%      22.2%
                                               *p*             \<0.0001   \<0.0001   \<0.0001   \<0.0001   \<0.0001   \<0.0001
                                     Total patient 97          95         87         87         90         79         90

###### 

**Impact of baseline patient characteristics on potency rates two years post**-**SBRT**

           **Characteristics**            **% Potent 2 years after SBRT**  ***p*value**  
  ------------------------------------- --------------------------------- -------------- -------------
                 **Age**                                                                        
                                                          ≤ 65 y/o pre-RT     66.7%          0.580
                                                          \>65 y/o pre-RT     47.4%             
                **Race**                                                                        
                                                                    White     51.2%          0.574
                                                                Non-white     57.4%             
           **Partner status**                                                                   
                                                                Partnered     54.3%          0.297
                                                            Non-partnered     55.0%             
   **Charlson comorbidity index(CCI)**                                                   
                                                                        0     58.9%         0.007\*
                                                                       ≥1     35.3%             
        **Body mass index(BMI)**                                                         
                                                                    \< 30     60.9%          0.943
                                                                     ≥ 30     38.5%             
        **Risk group(D'Amico's)**                                                        
                                                                 Low risk     54.8%          0.420
                                                   Intermediate-High Risk     54.2%             
             **Work status**                                                             
                                                                  Working     54.7%          0.173
                                                              Non-working     54.1%             
         **Pre-treatment SHIM**                                                          
                                                                     ≥ 22     40.91%         0.127
                                                                    \< 22     67.39%            
             **Sexual aid**                                                                     
                                                                     None     43.8%       0.010\*^\#^
                                                                      Yes     60.3%             
              **SBRT Dose**                                                                     
                                                                 36.25 Gy     50.0%          0.933
                                                              \< 36.25 Gy     55.0%             

\*Significant in univariate analysis; \# Significant multivariate analysis.

###### 

Sexual aid utilization following SBRT for prostate cancer

    **Sexual aid:**  **Oral**   **Vacuum**   **Suppository**   **Injection**
  ----------------- ---------- ------------ ----------------- ---------------
          **Start**   36.1%        1.0%           0.0%             0.0%
          **3 mon**   35.8%        1.1%           1.1%             0.0%
          **6 mon**   37.9%        2.3%           0.0%             0.0%
          **9 mon**   39.1%        2.3%           0.0%             1.1%
         **12 mon**   40.0%        4.4%           1.1%             0.0%
         **18 mon**   45.0%      3.80025          1.3%             1.3%
         **24 mon**   48.9%        3.8%           2.2%             2.2%

Adequate sexual function involves more than just possessing adequate erections \[[@B36]\]. The EPIC sexual domain allows for a more comprehensive and reliable assessment of a patients overall sexual function \[[@B37]\]. Average EPIC sexual scores showed a slow decline over the first two years following treatment: 77.6 (baseline); 68.7 (6 months); 63.2 (12 months); 61.9 (18 months); 59.3 (24 months) (Figure [1](#F1){ref-type="fig"}). At two year post-treatment, this change was statistically (p \< 0.001) and clinically significant (Figure [1](#F1){ref-type="fig"}). All sexual functions including orgasm declined with time in a similar manner (Figure [2](#F2){ref-type="fig"}a, d, Table [5](#T5){ref-type="table"}).

![**Average EPIC sexual domain scores at baseline and following SBRT for prostate cancer.** Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0--100 with higher values representing a more favorable health-related QOL.](1748-717X-8-256-1){#F1}

![**Average individual EPIC sexual function scores at baseline and following SBRT for prostate cancer. (a)** ability to have an erection-Question 8A of the EPIC-26; **(b)** ability to reach orgasm- Question 8B of the EPIC-26; **(c)** reliability of erection- Question 10 of the EPIC-26; **(d)** ability to function sexually- Question 11 of the EPIC-26. Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0--100 with higher values representing a more favorable health-related QOL.](1748-717X-8-256-2){#F2}

###### 

**Sexual functions following SBRT for prostate cancer**: **patient**-**reported responses to EPIC**-**26 questions 8A** (**ability to have an erection**), **8B** (**ability to reach orgasm**), **10** (**reliability of erections**) **and 11** (**ability to function sexually**)

                                     **Start**    **3**     **6**     **9**    **12**    **18**    **24**
  --------------------------------- ----------- --------- --------- --------- --------- --------- ---------
    **Ability to have an erection**                                                               
                     Very good-good    58.8%      51.6%     56.3%     43.7%     45.6%     41.8%     36.7%
                               Fair    34.0%      33.7%     26.4%     26.4%     25.6%     29.1%     31.1%
           Poor, very poor and none    7.2%       14.7%     17.2%     29.9%     28.9%     29.1%     32.2%
                                *p*              \<0.04    \<0.140   \<0.001   \<0.001   \<0.001   \<0.001
        **Ability to reach orgasm**                                                               
                     Very good-good    74.2%      56.8%     63.2%     51.7%     53.3%     53.2%     46.7%
                               Fair    18.6%      27.4%     18.4%     24.1%     24.4%     22.8%     25.6%
           Poor, very poor and none    7.2%       15.8%     18.4%     24.1%     22.2%     24.1%     27.8%
                                *p*              \<0.05     0.089    \<0.003   \<0.001   \<0.001   \<0.001
       **Reliability of erections**                                                               
       More than half-half the time    78.4%      66.3%     64.4%     55.2%     57.8%     54.4%     52.2%
            Less than half the time    21.6%      33.7%     35.6%     44.8%     42.2%     45.6%     47.8%
                                *p*              \<0.004   \<0.003   \<0.001   \<0.001   \<0.001   \<0.001
     **Function sexually(overall)**                                                               
                     Very good-good    63.9%      53.7%     52.9%     47.1%     47.8%     43.0%     40.0%
                               Fair    33.0%      29.5%     28.7%     24.1%     25.6%     24.1%     30.0%
                     Poor-very poor    3.1%       14.7%     16.1%     28.7%     26.7%     32.9%     30.0%
                                *p*              \<0.003   \<0.005   \<0.001   \<0.001   \<0.001   \<0.001
                             **N=**   **97**     **95**    **87**    **87**    **90**    **79**    **90**

Sexual bother may be more important to an individual patient than sexual function. As for the overall EPIC sexual domain scores, post-SBRT sexual bother scores were significantly lower than pre-SBRT scores at all time points (Figure [3](#F3){ref-type="fig"}, Table [6](#T6){ref-type="table"}). The proportion of men feeling that their sexual function was a moderate to big problem increased from 13.4% to 30% at 18 months post-SBRT (Figure [3](#F3){ref-type="fig"}, Table [6](#T6){ref-type="table"}).

![**EPIC sexual bother at baseline and following SBRT for prostate cancer-Question 12 of the EPIC-26.** Average sexual bother scores. Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0--100 with higher values representing a more favorable health-related QOL.](1748-717X-8-256-3){#F3}

###### 

Sexual brother following SBRT for prostate cancer (patient-reported responses to question 12 of the EPIC-26)

  **Sexual brother**          **Start**   **3 mon**   **6 mon**   **9 mon**   **12 mon**   **18 mon**   **24 mon**
  -------------------------- ----------- ----------- ----------- ----------- ------------ ------------ ------------
  No problem                   47.42%      40.86%      42.53%      37.93%       41.11%       41.25%       38.89%
  Very small-small problem     39.18%      40.86%      34.48%      40.23%       36.67%       28.75%       34.44%
  Moderate-big problem         13.40%      18.28%      22.99%      21.84%       22.22%       30.00%       26.67%

Pre-treatment total serum testosterone levels ranged from 4.4 nmol/L to 27.9 nmol/L with a median value of 11.4 nmol/L. 24.7% of patients were hypogonadal (total serum testosterone level below 8 nmol/L) prior to SBRT. At two years the median serum testosterone value of 10.7 nmol/L (range, 2.5- 26.4 nmol/L) was not significantly lower than the pre-treatment value (*p* = 0.07) (Figure [4](#F4){ref-type="fig"}a). The median absolute reduction was small (0.7 nmol/L) and the median percent reduction was 5.8%. The pre-treatment and 2-year post SBRT biochemical hypogonadism rates were not significantly different (data not shown). At one month post-treatment, the mean EPIC hormone score declined to 93.5 from a baseline of 95.6 (*p* = 0.04); it returned to baseline by 6 months post-treatment (Figure [4](#F4){ref-type="fig"}b).

![**Pre-and post-treatment testosterone levels and EPIC hormonal scores. (a)** Box**-**and**-**Whisker plot of total testosterone levels. The *p* values were from χ^2^-analysis with baseline testosterone levels. **(b)** Average EPIC hormonal scores. Thresholds for clinically significant changes in scores (½ standard deviation above and below the baseline) are marked with dashed lines. EPIC scores range from 0--100 with higher values representing a more favorable health-related QOL.](1748-717X-8-256-4){#F4}

Similar to prior reports, the median PB volume in this series was 11 cc \[[@B31]\]. The mean percentage of the PB receiving 29.5 Gy was 7.0% (range: 0--32.7%), with the potent and impotent groups receiving 6.3% (SD 6.5%) and 7.2% (SD 8.6%), respectively. The four patients who received 29.5 Gy to \> 25% of the PB were impotent two years following treatment.

Discussion
==========

Erectile dysfunction following prostate radiation therapy remains an ongoing challenge and critical quality of life issue \[[@B1]\]. Currently, there is limited data on sexual outcomes following SBRT for prostate cancer \[[@B29]\]. A better understanding of the sexual declines following SBRT would enable clinicians to provide more realistic expectations to patients as they weigh the complex treatment options \[[@B10]\]. Our prior report on sexual function following SBRT \[[@B30]\] utilized the SHIM questionnaire which primarily focuses on erectile function and is an inadequate measure of overall sexual function \[[@B5],[@B36]\]. In this study, we utilized the EPIC-26 sexual function domain to evaluate erectile function but also assess overall sexual function including orgasmic function and sexual bother.

For this analysis, potency was rigorously defined as the ability to have an erection firm enough for intercourse \[[@B4]\]. Forty five percent of our patients were potent prior to SBRT and these patients were included in this analysis. Still, they were elderly with relatively low baseline SHIM scores and high pretreatment sexual aid utilization (Table [1](#T1){ref-type="table"}). Even so, two years post-SBRT, 54% of these patients remained potent and 78% maintained an erection firm enough for masturbation and foreplay. As seen previously, the greatest decline in potency following radiation therapy occurred in the first year with stabilization afterwards \[[@B38]\]. These results are comparable to results with conventionally fractionated EBRT or brachytherapy \[[@B2],[@B10],[@B29]\].

The etiology of this early decline in potency is unclear but may involve exposure of the NVBs, crura or PB to excessive radiation. In this series, which included patients with unfavorable cancers, there was no attempt to spare the NVBs due to the concern that this may cause an unacceptably high rate of local failures \[[@B39]\]. Post-treatment sexual dysfunction may be exacerbated by high PB doses. With the aim of improving potency, we have modified our institutional protocol. To reduce the PB dose, we have restricted the PB dose to \< 25% of the volume receiving 29.5 Gy. Utilizing SBRT, this was easily achievable. PB doses below this did not correlate with impotence. We believe that such modifications have the potential to reduce the incidence and severity of impotence without increasing the risk of local failure.

Declining potency following SBRT suggests a need for approaches to improving long-term sexual outcomes. In this study, pre-treatment sexual aid usage was associated with increased potency two years following SBRT. Sexual aid utilization increased from a baseline of 37% to 49% at 24 months. Oral medication usage was common but vacuum device, urethral suppository, penile injection and/or penile prosthesis were rarely utilized. It is not clear why post-treatment utilization of these potentially effective therapies \[[@B10]\] was not higher. Possible explanations include patient's perception of potential discomfort, the high cost of such treatments or partner availability. Others have shown that while sexual function may be improved by the use of sexual aids, sexual bother may be enhanced \[[@B33]\].

Like other treatment modalities, this study shows that SBRT impacts all areas of sexual function including erections, orgasm and overall satisfaction \[[@B40],[@B41]\]. For example, only 46.7% of men two years following SBRT reported at least a good ability to reach orgasm compared to 74% prior to treatment (Table [5](#T5){ref-type="table"}). The etiology of this decline in the ability to obtain orgasm is unclear but could be related to hemospermia, reduced ejaculate and/or painful ejaculation \[[@B42]-[@B45]\]. To better assess the etiology of orgasmic dysfunction, our future studies will employ an instrument to assess the effect of SBRT on ejaculation \[[@B46]\].

Bother may be a better indicator than function on how a treatment impacts an individual patient's quality of life \[[@B47]\]. Sexual bother is defined as the degree of interference or annoyance caused by limitations in sexual function and is dependent on an individual's pre-treatment erectile function, libido and partner status \[[@B33]\]. In general, previously potent men report a higher rate of bother following treatment than impotent men \[[@B48]\]. In this series of potent men, sexual bother slowly increased during the first two years following SBRT treatment (Figure [3](#F3){ref-type="fig"}, Table [6](#T6){ref-type="table"}). Similar to other radiation modalities, this rate plateaued at 12--24 months following treatment with 30-40% of men reporting sexual bother as a moderate to big problem \[[@B2],[@B49]\]. As in other series, sexual bother scores were better than sexual function scores.

Our study has several limitations. The penile bulb may not be the critical component of the erectile apparatus, but may be a surrogate for the crura in conventional radiation therapy treatment planning \[[@B16]\]. The utilization of non-coplanar beams in SBRT treatment could yield unexpectedly high doses to the crura \[[@B50]\]. Future studies should determine the crura dose during SBRT treatment and its impact on post-SBRT potency. In addition, the pretreatment utilization of sexual aids in our patients was high compared to previous reports \[[@B29]\]. The etiology is unclear but may limit the generalizability of this study.

Conclusions
===========

SBRT was well-tolerated for these patients with clinically localized prostate cancer. Men with preserved potency undergoing SBRT monotherapy for prostate cancer have sexual outcomes comparable to those reported for alternative radiation modalities within the first 24 months after treatment. Although most men retained sexual function, declining potency following treatment suggest a need for new approaches to improve long-term sexual outcomes.
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